Program
abrysvo
Also written as “RSVpreF”, “RSVpreF Vaccine” and “RSVpreF (Regimen A)”.
Its studies are mostly in Respiratory Tract Infections · Respiratory Syncytial Virus Infections · COVID-19 · Influenza, Human, led by 2 companies.
Drug pageAbrysvo: every studyAll 19 studies of it, academic ones too, with its approvals, label and forms.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Pfizerits history only | 177 open or running | phase 3since Jun 3, 2020 | Jun 3, 2020 | Jan 18, 2027phase 3 · NCT05035212 |
| Hvivo | 10 open or running | phase 2since Feb 12, 2021 | Feb 12, 2021 | none ahead |
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and studies of Hvivo only; the figures above count every company.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Feb 12, 2021First study: phase 2 study in Respiratory Syncytial Virus InfectionsFirst studyNCT04785612 · 70 enrolled · United Kingdom
TargetBeta
A vaccine: it acts on a pathogen, not a human gene.
“Fusion glycoprotein F0 vaccine antigen”ChEMBL 37, by rule
Studies
The one study Hvivo leads. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT04785612Respiratory Syncytial Virus Infections · United Kingdom | 2 | Completed | Apr 8, 2021 | 70 |
How it is read
Names in the registry
- “RSVpreF”, 10 entries
- “RSVpreF Vaccine”, 2 entries
- “RSVpreF (Regimen A)”, 1 entry
- “RSVpreF (Regimen B)”, 1 entry
- “RSVpreF vaccine”, 1 entry
Conditions, from the studies’ own filings
- Respiratory Tract Infections, 4 studies
- Respiratory Syncytial Virus Infections, 2 studies
- COVID-19, 1 study
- Influenza, Human, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.